

16
0300
ATTORNEY DOCKET NO: 84894-602

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT Gordon W. Glazner * 8
SERIAL NO: 09/878,918
FILED June 13, 2001
FOR Therapeutic Uses for IP3 Receptor-Mediated Calcium
 Channel Modulators

Commissioner of Patents
Washington, D.C., 20231
U.S.A.

DISCLOSURE SUBMISSION

STATEMENT UNDER 37 C.F.R. §1.56

Dear Sir:

The citations on the attached sheet, copies attached, may be material to the examination of the above identified application and are, therefore, submitted in compliance with the duty of disclosure as defined in 37 C.F.R. §1.56. The Examiner is requested to make these citations of official record in the application.

The Disclosure Submission Statement under 37 C.F.R. §1.56 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist or that any one or more of these citations constitute prior art under 35 U.S.C. §102.

Respectfully submitted

Gordon W. Glazner


PER: Michael R. Williams
Michael R. Williams
Registration No: 45,333

/dj
January 10, 2002

Michael R. Williams Winnipeg, Manitoba, Canada
Telephone (204) 947-1429 FAX (204) 942-5723

FORM PTO 1449 U.S. Department of Commerce Patent and Trademark Office INFORMATION DISCLOSURE CITATION	Attorney Docket No. 84894-602	Serial No. 09/878,918
	Applicant Gordon W. Glazner	
	Filing Date June 13 th , 2001	Group

U.S. PATENT DOCUMENTS



Examiner Initial	Document Number	DATE	NAME	Class	Sub Class	Filing Date
	6,060,587	05/09/2000	Weiner et al.			
	5,985,926	11/16/1999	Leung et al.			
	6,159,684	12/12/2000	Cujec et al.			
	5,821,046	10/13/1998	Karn et al.			
	6,024,965	20/15/2000	Van Baalen et al.			
	5,606,026	02/25/1997	Rodman			
	5,637,461	06/10/1997	Gold et al.			
	5,821,072	10/13/1998	Schwartz et al.			
	5,843,925	12/01/1998	Backer et al.			
	6,123,943	09/26/2000	Baba et al.			
	6,051,386	04/18/2000	Lerner et al.			
	6,069,296	05/30/2000	Horovitz et al.			
	5,847,074	12/08/1998	Yamasaki et al.			
	5,519,163	05/21/1996	Gibbs et al.			
	5,352,810	10/04/1994	Brufani et al.			
	6,107,327	08/22/2000	Jirousek et al.			
	6,214,540	04/10/2001	DeVico et al.			

FOREIGN PATENT DOCUMENTS

	Document Number	DATE	COUNTRY	Class	Sub Class	
	WO 99/02185	01/21/1999	International			
	WO 00/78969	12/28/2000	International			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages)

	Masashi Nakagawa et al., "Structures of Xestospongins A,B,C and D, novel vasodilative compounds from marine sponge, <i>Xestospongia Exigua</i> ", <u>Tetrahedron Letters</u> , (1984), Vol. 25, No. 30, P. 3227-3230.
	Peter M. Vassilev et al., "Inhibition of Ca T1 channel activity by a noncompetitive IP ₃ antagonist", <u>Biochemical and Biophysical Research Communications</u> , (2001), 280, P. 145-150.



	Juliette Gafni et al., " Xestospingins: Potent Membrane Permeable Blockers of the inositol 1,4,5-Trisphosphate receptor", <u>Neuron</u> , September 1997, Vol. 19, P. 723-733.
	Michael J. Tisdale, "Protein Loss in Cancer Cachexia", <u>Science</u> , 29 September 2000, Vol. 289, P. 2293-2294.
	Denis C. Guttridge, "NF-kB-Induced Loss of <i>MyoD</i> Messenger RNA: Possible Role in Muscle Decay and Cachexia", <u>Science</u> , 29 September 2000, Vol. 289, P. 2363-2366.
	Eric G. Lee et al., "Failure to Regulate TNF-Induced NF-kB and Cell Death Responses in A20-Deficient Mice", <u>Science</u> , 29 September 2000, Vol. 289, P. 2350-2354.
	Qinghua Hu et al., "[Ca ²⁺] _i Oscillation Frequency Regulates Agonist-stimulated NF-kB Transcriptional Activity", <u>The Journal of Biological Chemistry</u> , 28 November 1999, Vol. 274 No. 48, P. 33995-33998.

Examiner	Date Considered